Please enable JavaScript.

Coggle requires JavaScript to display documents.

Non-Alcoholic Fatty Liver Disease (NAFLD) - Coggle Diagram

- - - - Special consideration should be given to gradual weight loss, as up to one fifth of patients, particularly those with pronounced and accelerated weight loss, develop portal fibrosis or inflammation, possibly due to an increase in circulating levels of free fatty acids resulting from adipose tissue mobilization, oxidative stress, lipid peroxidation, and cytokine induction, which together worsen liver damage
  - - - In patients treated with bariatric surgery, it has been found to improve insulin resistance, alterations in glucose metabolism, hypertension, plasma lipids, transaminases, hepatic steatosis, steatohepatitis, and fibrosis.
  - - - Decreases lipid absorption and promotes weight loss, but it has not been successful for the treatment of NAFLD.
    - - Antioxidant associated with the improvement of steatosis and steatohepatitis in patients without diabetes, it is currently recommended for the treatment of NAFLD
    - - A member of the nuclear receptor superfamily, it is responsible for the regulation of genes involved in the control of bile acids, lipids, and glucose metabolism.
    - - Reduces insulin resistance, dyslipidemia and steatosis.